Sponsored By:

7 Biotechnology Stocks to Sell Now

GHDX, ACOR, AMRN, EXEL, TSRX, DSCO, ACHN slump in weekly rankings

   

For the current week, the overall ratings of seven biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Genomic Health, Inc. (GHDX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock price has fallen 14.6% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. For a full analysis of GHDX stock, visit Portfolio Grader.

Acorda Therapeutics, Inc. (ACOR) earns a D this week, falling from last week’s grade of C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. At $29.48, the stock is below the 50-day moving average of $32.26. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

This week, Amarin Corporation Plc Sponsored ADR’s (AMRN) rating worsens to a D from the company’s C rating a week ago. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock receives F’s in Earnings Growth, Earnings Revisions, Equity and Cash Flow. As of Dec. 24, 2013, 17.3% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. To get an in-depth look at AMRN, get Portfolio Grader’s complete analysis of AMRN stock.

Exelixis, Inc. (EXEL) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Margin Growth and Sales Growth also get F’s. As of Dec. 24, 2013, 25.3% of outstanding Exelixis, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

Trius Therapeutics, Inc. (TSRX) earns a D this week, falling from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.

This week, Discovery Laboratories, Inc.’s (DSCO) rating worsens to a D from the company’s C rating a week ago. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.

Achillion Pharmaceuticals, Inc. (ACHN) earns a D this week, moving down from last week’s grade of C. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of Dec. 24, 2013, 18% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. For a full analysis of ACHN stock, visit Portfolio Grader.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/12/7-biotechnology-stocks-to-sell-now-ghdx-acor-amrn-27/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.